Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Chief Legal & Admin Officer | March 15, 2026 | March 17, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP & General Counsel | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 15, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,943 |
Reported balance
After 2026-03-15 transaction · row 1
1 source rowRow 1 · 2026-03-15 · Grant · Acquired 20,646 · Balance 107,943 F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 8,325 |
Reported balance
After 2026-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-15 · Grant · Acquired 8,325 · Balance 8,325 F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 22,820 |
Reported balance
After 2026-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-15 · Grant · Acquired 22,820 · Balance 22,820 F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 693,396 |
Last balance in matching sequence
After 2025-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 34,035 · Balance 718,396 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-15 · Sale · Disposed 25,000 · Balance 693,396 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 999 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 999 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024.
F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 18, 2023 02:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,929 | $18.08 | $34,876.32 |
DisclosureSEC source: 0000939767-23-000024 · wf-form4_167668805342567.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,716 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 125,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 01:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $16.71 | $119,927.67 |
DisclosureSEC source: 0000939767-22-000114 · wf-form4_166873595249414.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,645 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 30, 2021. F6 · balance_after: Includes 130,199 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:44 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $21.49 | $154,233.73 |
DisclosureSEC source: 0000939767-22-000086 · wf-form4_165975024915430.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,804 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:44 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 28,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000086 · wf-form4_165975024915430.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,981 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement of certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On August 3, 2022, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on August 15, 2023, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 144,674 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 16, 2022 Filed Nov 18, 2022 01:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,000 | $20.07 | $361,260.00 |
DisclosureSEC source: 0000939767-22-000114 · wf-form4_166873595249414.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,822 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.29. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| May 15, 2022 Filed May 18, 2022 00:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 5,349 | $20.08 | $107,407.92 |
DisclosureSEC source: 0000939767-22-000060 · wf-form4_165283312363016.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,031 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 130,199 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,144 shares of Exelixis, Inc. common stock acquired on April 29, 2022, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 13,283 | $22.00 | $292,226.00 |
DisclosureSEC source: 0000939767-22-000040 · wf-form4_164868581583503.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 4,717 | $22.00 | $103,774.00 |
DisclosureSEC source: 0000939767-22-000040 · wf-form4_164868581583503.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,519 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · balance_after: Includes 144,482 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 67,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000037 · wf-form4_164679097435243.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,236 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 144,482 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,000 | $20.00 | $360,000.00 |
DisclosureSEC source: 0000939767-22-000033 · wf-form4_164609706715946.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,361 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 76,607 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 11,209 | $18.59 | $208,375.31 |
DisclosureSEC source: 0000939767-22-000020 · wf-form4_164514645487379.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,361 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,017 | $18.59 | $18,906.03 |
DisclosureSEC source: 0000939767-22-000020 · wf-form4_164514645487379.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,570 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 76,607 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:26 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,621 | $17.00 | $44,557.00 |
DisclosureSEC source: 0000939767-21-000111 · wf-form4_163979079438564.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,587 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:26 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000111 · wf-form4_163979079438564.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,208 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 9,994 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 108,812 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 46,743 | $18.10 | $846,048.30 |
DisclosureSEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,214 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,311 | $18.10 | $23,729.10 |
DisclosureSEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,957 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,557 | $18.10 | $118,681.70 |
DisclosureSEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,268 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. F2 · balance_after: Includes 103,815 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,117 | $22.03 | $112,727.51 |
DisclosureSEC source: 0000939767-21-000098 · wf-form4_163598474276526.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,825 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 15, 2021 Filed Oct 16, 2021 00:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 12,883 | $22.02 | $283,683.66 |
DisclosureSEC source: 0000939767-21-000088 · wf-form4_163434323702285.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,942 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,593 | $20.63 | $156,643.59 |
DisclosureSEC source: 0000939767-21-000086 · wf-form4_163339274187742.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,825 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 28,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000086 · wf-form4_163339274187742.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,418 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,220 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| May 17, 2021 Filed Nov 18, 2022 01:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,000 | $25.39 | $457,020.00 |
DisclosureSEC source: 0000939767-22-000114 · wf-form4_166873595249414.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,822 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.09 to $25.71. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 144,674 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 18 shares of common stock acquired on October 31, 2022, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 00:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,000 | $25.03 | $450,540.00 |
DisclosureSEC source: 0000939767-21-000041 · wf-form4_161965479571792.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,248 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 193,455 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 01:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 57,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000034 · wf-form4_161499247200887.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,248 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 193,455 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,685 | $21.91 | $36,918.35 |
DisclosureSEC source: 0000939767-21-000018 · wf-form4_161361067836336.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,113 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on December 4, 2019. F2 · balance_after: Includes 136,320 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 15,365 | $22.56 | $346,634.40 |
DisclosureSEC source: 0000939767-21-000011 · wf-form4_161257780457140.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,798 F8 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 59,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000011 · wf-form4_161257780457140.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,163 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F5 · date: On September 20, 2019, the Reporting Person was granted a PSU award the under 2017 Equity Incentive Plan covering 118,821 shares of common stock (such award, the "2019 Award," and such shares, the "Target Shares"). The 2019 Award generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by Committee; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the 2019 Award provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the 2019 Award. F6 · shares: On February 3, 2021, the Committee determined the maximum performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 200% of the Target Shares subject to the 2019 Award. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and the remaining 25% of the Target Shares will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F7 · balance_after: Includes 140,818 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000011 · wf-form4_161257780457140.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,752 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 4,998 shares of common stock (such award, the "2018 Award"). The 2018 Award generally vests as follows: (i) 50% of the original number of shares subject to the 2018 Award vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria related to clinical trial enrollment or positive top-line results (the "2018 Goal"); and (ii) 50% of the original number of shares subject to the 2018 Award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On February 3, 2021, the Committee convened to determine that the 2018 Goal had been achieved, resulting in the immediate vesting of 50% of the 2018 Award, and the remaining 50% will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 111,112 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-21-000001 · wf-form4_160998251861758.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-21-000001 · wf-form4_160998251861758.xml · derivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $1.90 | $38,000.00 |
DisclosureSEC source: 0000939767-21-000001 · wf-form4_160998251861758.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $7.27 | $218,100.00 |
DisclosureSEC source: 0000939767-21-000001 · wf-form4_160998251861758.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Jan 7, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000001 · wf-form4_160998251861758.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,754 F1 · balance_after: Includes 108,613 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-20-000153 · wf-form4_160566122128587.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $7.27 | $218,100.00 |
DisclosureSEC source: 0000939767-20-000153 · wf-form4_160566122128587.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,131 | $20.16 | $42,960.96 |
DisclosureSEC source: 0000939767-20-000153 · wf-form4_160566122128587.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,254 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on September 22, 2016. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,557 | $20.16 | $132,189.12 |
DisclosureSEC source: 0000939767-20-000153 · wf-form4_160566122128587.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,385 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,573 | $20.16 | $31,711.68 |
DisclosureSEC source: 0000939767-20-000153 · wf-form4_160566122128587.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,942 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 12, 2019. F2 · balance_after: Includes 108,613 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 46,742 | $21.79 | $1,018,508.18 |
DisclosureSEC source: 0000939767-20-000138 · wf-form4_160375705110335.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,515 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on October 22, 2020. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 178,231 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000138 · wf-form4_160375705110335.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,257 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 20, 2019, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 118,821 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On October 22, 2020, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 75% of the Target Shares, and 75% of the Target Shares will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2021. F4 · balance_after: Includes 128,174 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 21, 2020 Filed Oct 24, 2020 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 39,742 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-20-000135 · wf-form4_160349809329524.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 39,742 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018. Read SEC document |
| October 21, 2020 Filed Oct 24, 2020 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 39,742 | $21.95 | $872,336.90 |
DisclosureSEC source: 0000939767-20-000135 · wf-form4_160349809329524.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,026 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.76 to $22.45. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 21, 2020 Filed Oct 24, 2020 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 39,742 | $7.27 | $288,924.34 |
DisclosureSEC source: 0000939767-20-000135 · wf-form4_160349809329524.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 10,258 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-20-000132 · wf-form4_160099218384042.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,742 Underlying: Common Stock · 10,258 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 10,258 | $26.14 | $268,144.12 |
DisclosureSEC source: 0000939767-20-000132 · wf-form4_160099218384042.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,026 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.30. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 10,258 | $7.27 | $74,575.66 |
DisclosureSEC source: 0000939767-20-000132 · wf-form4_160099218384042.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 20,000 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $26.11 | $522,200.00 |
DisclosureSEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,026 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.42. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $7.27 | $145,400.00 |
DisclosureSEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 190,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Common Stock, became fully exercisable on September 16, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.